C
39.75
-0.01 (-0.03%)
| Penutupan Terdahulu | 39.76 |
| Buka | 39.76 |
| Jumlah Dagangan | 2,014,036 |
| Purata Dagangan (3B) | 2,610,419 |
| Modal Pasaran | 6,150,569,472 |
| Harga / Jualan (P/S) | 358.74 |
| Harga / Buku (P/B) | 12.62 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -205.18% |
| EPS Cair (TTM) | -1.88 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.55% |
| Nisbah Semasa (MRQ) | 14.37 |
| Aliran Tunai Operasi (OCF TTM) | -162.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -106.95 M |
| Pulangan Atas Aset (ROA TTM) | -28.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Centessa Pharmaceuticals plc | Menurun | Menaik |
AISkor Stockmoo
-1.1
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.13 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.50% |
| % Dimiliki oleh Institusi | 94.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 31 Mar 2026 | 19,963,157 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 11,430,455 |
| Index Venture Life Associates Vi Ltd | 31 Mar 2026 | 9,961,789 |
| Ecor1 Capital, Llc | 31 Mar 2026 | 6,000,000 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2026 | 3,574,048 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Jun 2026 | CNBC | Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |